There are 2789 resources available
582P - Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
Presenter: Matthew Smith
Session: ePoster Display
583P - Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Presenter: Vincenza Conteduca
Session: ePoster Display
584P - Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Stephane Oudard
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display
586P - Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: ePoster Display
587P - Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
Presenter: Alicia Morgans
Session: ePoster Display
588P - Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial
Presenter: Klara Kvorning Ternov
Session: ePoster Display
589P - Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Enrique Perez Navarro
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
524P - A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Presenter: Melissa Johnson
Session: ePoster Display